PTGX
Protagonist Therapeutics, Inc. (PTGX)
Last Price$59.76.8%
Market Cap$3,532.4M
LTM Total Assets
$744.7M
YoY Growth
+108.1%
3Y CAGR
+28.9%
5Y CAGR
+36.9%
Stock quality & Intrinsic value
7/10
65.3% overvalued

Protagonist Therapeutics, Inc. Total Assets

Annual
Quarterly
LTM
Crunching data... Almost there!
Dec'14Dec'15Dec'16Dec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24
Total Assets
$10.3M
$14.8M
$94.0M
$163.7M
$139.5M
$154.9M
$324.5M
$347.7M
$247.9M
$358.0M
$744.7M
PTGX
Key metrics and insights to make informed decisions.
View full analysis
Overvalued or undervalued?
Check the intrinsic value for PTGX and see if it's the right time to invest.
Dive in

Protagonist Therapeutics, Inc. (PTGX) Total Assets comparison analysis

PTGX key stats

USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Dec'14Dec'15Dec'16Dec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24
% growth
0.0
0.0%
0.0
0.0%
0.0
0.0%
20.1
0.0%
30.9
54.1%
0.2
(99.3%)
28.6
12,293.1%
27.4
(4.4%)
26.6
(2.8%)
60.0
125.7%
434.4
624.1%
Cost of Goods Sold (COGS)0.00.20.30.00.00.00.02.81.00.00.0
% margin
0.0
0.0%
(0.2)
0.0%
(0.3)
0.0%
20.1
100.0%
30.9
100.0%
0.2
100.0%
28.6
100.0%
24.6
89.9%
25.5
96.1%
60.0
100.0%
434.4
100.0%
Operating Expenses9.314.832.758.073.280.893.1153.2158.0153.7181.6
Research & Development Expenses (R&D)7.511.825.746.259.565.074.5126.0126.2120.2138.1
Selling, General & Administrative Expenses (SG&A)1.93.07.011.813.715.718.627.231.733.543.5
(9.3)
0.0%
(14.8)
0.0%
(32.7)
0.0%
(37.9)
(188.9%)
(42.3)
(136.7%)
(80.5)
(34,857.6%)
(64.5)
(225.4%)
(125.8)
(460.0%)
(131.4)
(494.2%)
(93.7)
(156.1%)
252.8
58.2%
Interest Income0.00.00.20.92.62.80.90.44.114.926.3
Interest Expense0.00.00.00.00.00.20.60.00.00.00.0
Pre-tax Income(11.1)(14.9)(37.2)(37.0)(39.7)(77.9)(64.8)(125.6)(127.4)(79.0)279.4
% effective tax rate
1.8
(15.8%)
0.1
(0.4%)
4.2
(11.2%)
(0.4)
1.1%
(0.8)
2.0%
(0.7)
0.9%
1.3
(2.0%)
(2.9)
2.3%
(4.0)
3.1%
0.0
0.0%
4.2
1.5%
% margin
(11.1)
0.0%
(14.9)
0.0%
(37.2)
0.0%
(37.0)
(184.2%)
(38.9)
(125.9%)
(77.2)
(33,414.3%)
(66.2)
(231.1%)
(122.6)
(448.2%)
(123.4)
(464.3%)
(79.0)
(131.6%)
275.2
63.3%
EPS(1.88)(2.52)(5.72)(2.09)(1.74)(2.98)(1.92)(2.65)(2.52)(1.39)4.47
Diluted EPS(1.88)(2.52)(5.72)(2.09)(1.74)(2.98)(1.92)(2.65)(2.52)(1.39)4.23
% margin
(9.1)
0.0%
(14.5)
0.0%
(32.3)
0.0%
(36.6)
(182.2%)
(39.2)
(126.7%)
(78.3)
(33,898.7%)
(63.7)
(222.4%)
(123.1)
(449.9%)
(131.4)
(494.2%)
(90.3)
(150.6%)
252.8
58.2%

Discover more Stock Ideas

FAQ

1) What is Protagonist Therapeutics, Inc.'s Total Assets?

As of today, Protagonist Therapeutics, Inc.'s last 12-month Total Assets is $744.7M, based on the financial report for Dec 31, 2024 (Q4’2024).

2) What is Protagonist Therapeutics, Inc.'s Total Assets growth rate?

Over the last year, Protagonist Therapeutics, Inc.'s Total Assets growth was 108.1%. The average annual Total Assets growth rates for Protagonist Therapeutics, Inc. have been 22.6% over the past three years, 36.9% over the past five years.

3) Is Protagonist Therapeutics, Inc.'s Total Assets growth rate Good?

Over the last year, Protagonist Therapeutics, Inc.'s Total Assets growth was 108.1%, which is higher than industry growth of (0.1%). It indicates that Protagonist Therapeutics, Inc.'s Total Assets growth is Good.

4) How does Protagonist Therapeutics, Inc.'s Total Assets growth rate compare to its peers?

Over the last year, Protagonist Therapeutics, Inc.'s Total Assets growth was 108.1%, which is higher than peer median growth of 2.5%. The list of peers includes REGN, BNTX, VRTX, RPRX, UTHR, BMRN, BGNE, ALNY, SMMT, ARGX etc.